Metastatic Hormone-Receptor Positive Breast Cancer

The expert panelists highlight data from the virtual San Antonio Breast Cancer Symposium 2020, focusing on hormone receptor-positive breast cancer.

Data from the following abstracts are discussed:

• “GS1-01. Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Combined with Adjuvant Endocrine Therapy for High Risk Early Breast Cancer” (O’Shaughnessy et al, SABCS 2020)

• “GS1-02. Phase III Study of Palbociclib Combined With Endocrine Therapy (ET) in Patients With Hormone-Receptor-Positive (HR+), HER2-Negative Primary Breast Cancer and With High Relapse Risk After Neoadjuvant Chemotherapy (NACT): First Results From PENELOPE-B” (Loibl et al, SABCS 2020)

• “GS4-01. Results from CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor + (HR+) Metastatic Breast Cancer (MBC) Who Have Previously Received a Taxane” (O’Shaughnessy et al, SABCS, 2020)

• “GS3-00. First Results From a Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy (ET) +/- Chemotherapy (CT) in Patients (pts) with 1-3 Positive Nodes, Hormone Receptor-Positive (HR+) and HER2-negative (HER2-) Breast Cancer (BC) with Recurrence Score (RS) < 25: SWOG S1007 (RxPonder)” (Kalinsky et al, SABCS 2020)

• “GS2-02. 12-Year Results of Anastrozole Versus Tamoxifen For the Prevention of Breast Cancer in Postmenopausal Women With Locally Excised Ductal Carcinoma In-Situ” (Sestak et al, SABCS 2020)